Equibles does not estimate personal net worth.
Get an email with a short summary when Stoke Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get STOK alertsThe proxy statement of Stoke Therapeutics, Inc. reports total compensation of $2,269,955 for Jason Hoitt in fiscal 2025, including a base salary of $494,401. Jason Hoitt has spoken on 2 earnings calls and 2 other investor events across 1 company, most recently for Stoke Therapeutics, Inc. on August 3, 2026. Stoke Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Stoke Therapeutics, Inc. includes Ian F. Smith (CEO and Board Member), Arthur Tzianabos (Chairman), Thomas E. Leggett (CFO) and 6 others.
“Today, I'll focus on three areas, the market opportunity in Dravet syndrome, how we think about label and access, and the progress we're making toward a potential U.S. launch.”
“Coincidentally, Skyclaris and CalSody, also from Biogen, are good examples of observed data being added to the Section 14 of their labels.”
“As you just heard, EMPER is nearly fully enrolled, which puts us into a roughly 18-month window for the earliest potential U.S. approval and launch. Today, I'll share how we're preparing to deliver Zeriva Nursen to all patients who could potentially benefit in the U.S. I'll start with the patient population.”
Proxy statement
Start not stated–present
Last confirmed April 22, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Stoke Therapeutics, Inc. (STOK) | Chief Patient Officer | $494,401 | $2,269,955 |
